Publication:
Autoimmune retinopathies: a report of 3 cases

dc.contributor.coauthorOray, Merih
dc.contributor.coauthorKir, Nur
dc.contributor.coauthorTuncer, Samuray
dc.contributor.coauthorOnal, Sumru
dc.contributor.coauthorTugal-Tutkun, Ilknur
dc.contributor.departmentN/A
dc.contributor.kuauthorÖnal, Sumru
dc.contributor.kuprofileOther
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid52359
dc.date.accessioned2024-11-09T23:43:50Z
dc.date.issued2013
dc.description.abstractPurpose: To describe 3 representative cases of autoimmune retinopathy (AIR). Methods: Clinical records of patients with a diagnosis of AIR were analyzed for demographic data, clinical findings, ancillary and laboratory tests, and treatment employed. Results: Three female patients diagnosed with AIR had bilateral reduction of electroretinogram amplitudes and elevation of visual field threshold within the central 30 degrees of the visual field that was disproportionately more severe than the clinical findings of retinal degeneration. The diagnoses were cancer-associated retinopathy, non-neoplastic AIR, and hereditary retinal dystrophy with secondary inflammation. Optic nerve involvement was also present in all cases. The patient with non-neoplastic AIR was successfully treated with systemic corticosteroids and immunomodulatory agents. Conclusion: High index of suspicion is essential for an early diagnosis of AIR. Visual function and electrophysiological tests should be included in the initial workup of patients who present with suggestive clinical signs and symptoms of AIR.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsorshipNovartis Pharma AG
dc.description.sponsorshipNovartis Turkey
dc.description.sponsorshipAbbott Turkey
dc.description.sponsorshipIRIS (Institut de Recherches Internationales Servier)
dc.description.sponsorshipXOMA (US) LLC
dc.description.sponsorshipKowa Company Ilknur Tugal-Tutkun has received financial support outside the submitted work, including honoraria from IRIS (Institut de Recherches Internationales Servier), Novartis Pharma AG, and XOMA (US) LLC and Kowa Company, a research grant from Novartis Pharma AG, and travel grants from Novartis Turkey and Abbott Turkey. No government or nongovernment funding support has been obtained.
dc.description.volume21
dc.identifier.doi10.3109/09273948.2013.799215
dc.identifier.eissn1744-5078
dc.identifier.issn0927-3948
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-84887910850
dc.identifier.urihttp://dx.doi.org/10.3109/09273948.2013.799215
dc.identifier.urihttps://hdl.handle.net/20.500.14288/13563
dc.identifier.wos326987300002
dc.keywordsAutoimmune retinopathy
dc.keywordsCancer-associated retinopathy
dc.keywordsElectroretinogram
dc.keywordsOptical coherence tomography
dc.keywordsVisual field cancer-associated retinopathy
dc.keywordsOccult outer retinopathy
dc.keywordsTerm-follow-up
dc.keywordsAntiretinal antibodies
dc.keywordsIntermediate uveitis
dc.keywordsRecoverin
dc.keywordsAutoantibodies
dc.keywordsAutoantigen
dc.keywordsEnolase
dc.languageEnglish
dc.publisherTaylor and Francis Inc
dc.sourceOcular Immunology and Inflammation
dc.subjectOphthalmology
dc.titleAutoimmune retinopathies: a report of 3 cases
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-4036-922X
local.contributor.kuauthorÖnal, Sumru

Files